Impact of PSMA PET on Prostate Cancer Management.

Humans Male Antigens, Surface Neoplasm Staging Positron Emission Tomography Computed Tomography / methods Prospective Studies Prostatic Neoplasms / therapy Radiopharmaceuticals / therapeutic use Prostate-Specific Antigen
Clinical decision-making Drug therapy Neoplasm staging Positron-emission tomography Prognosis Prostatic neoplasms Radiotherapy Surgery Theranostic nanomedicine

Journal

Current treatment options in oncology
ISSN: 1534-6277
Titre abrégé: Curr Treat Options Oncol
Pays: United States
ID NLM: 100900946

Informations de publication

Date de publication:
Feb 2024
Historique:
accepted: 11 01 2024
medline: 19 2 2024
pubmed: 25 1 2024
entrez: 25 1 2024
Statut: ppublish

Résumé

PSMA-PET has been a practice-changing imaging biomarker for the management of men with PCa. Research suggests improved accuracy over conventional imaging and other PET radiotracers in many contexts. With multiple approved PSMA-targeting radiotracers, PSMA PET will become even more available in clinical practice. Its increased use requires an understanding of the prospective data available and caution when extrapolating from prior trial data that utilized other imaging modalities. Future trials leveraging PSMA PET for treatment optimization and management decision-making will ultimately drive its clinical utility.

Identifiants

DOI: 10.1007/s11864-024-01181-9 PMID: 38270802
pubmed: 38270802
doi: 10.1007/s11864-024-01181-9
pii: 10.1007/s11864-024-01181-9
doi:

Substances chimiques

Antigens, Surface 0
Radiopharmaceuticals 0
Prostate-Specific Antigen EC 3.4.21.77

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

191-205

Subventions

Organisme : NIGMS NIH HHS
ID : T32 GM008042
Pays : United States
Organisme : NCI NIH HHS
ID : U2C CA271894
Pays : United States
Organisme : NIH HHS
ID : T32GM008042
Pays : United States
Organisme : NIH HHS
ID : U2CCA271894
Pays : United States

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.

Auteurs

Adam B Weiner (AB)

Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA. abweiner@mednet.ucla.edu.
Institute for Precision Health, University of California-Los Angeles, Los Angeles, CA, USA. abweiner@mednet.ucla.edu.

Raag Agrawal (R)

Institute for Precision Health, University of California-Los Angeles, Los Angeles, CA, USA.
Department of Human Genetics, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.
Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, CA, USA.

Luca F Valle (LF)

Department of Radiation Oncology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.
Veterans Affairs Greater Los Angeles Healthcare System, Los Angeles, CA, USA.

Ida Sonni (I)

Department of Radiological Sciences, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.
Department of Clinical and Experimental Medicine, University Magna Graecia, Catanzaro, Italy.

Amar U Kishan (AU)

Department of Radiation Oncology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.

Matthew B Rettig (MB)

Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.
Department of Medicine, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.

Steven S Raman (SS)

Department of Radiological Sciences, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.

Jeremie Calais (J)

Ahmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.

Paul C Boutros (PC)

Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.
Institute for Precision Health, University of California-Los Angeles, Los Angeles, CA, USA.
Department of Human Genetics, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.
Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, CA, USA.

Robert E Reiter (RE)

Department of Urology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, CA, USA.
Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, CA, USA.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Impact of PSMA PET on Prostate Cancer Management.
questionsmedicales.fr › Facteurs biologiques › Antigènes › Antigènes de surface › Impact of PSMA PET on Prostate Cancer Management.
questionsmedicales.fr › Diagnostic › Pronostic › Stadification tumorale › Impact of PSMA PET on Prostate Cancer Management.
questionsmedicales.fr › Diagnostic › Techniques et procédures diagnostiques › Techniques de diagnostic radioisotopique › Scintigraphie › Tomoscintigraphie › Tomographie par émission de positons › Tomographie par émission de positons couplée à la tomodensitométrie › Impact of PSMA PET on Prostate Cancer Management.
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études prospectives › Impact of PSMA PET on Prostate Cancer Management.
questionsmedicales.fr › Maladies urogénitales › Tumeurs de l'appareil urogénital › Tumeurs de l'appareil génital mâle › Tumeurs de la prostate › Impact of PSMA PET on Prostate Cancer Management.
questionsmedicales.fr › Actions chimiques et utilisations › Utilisations spécialisées de produits chimiques › Produits chimiques de laboratoire › Indicateurs et réactifs › Radiopharmaceutiques › Impact of PSMA PET on Prostate Cancer Management.
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Antigène spécifique de la prostate › Impact of PSMA PET on Prostate Cancer Management.